InsidersTradesSigma
Follow the 메타바이오메드 share price and the full management transaction log of the company, a listed issuer based in South Korea. Shares trade on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, 메타바이오메드 has published 4 public disclosures. Market capitalisation: €102.3bn. The latest transaction was filed on 27 April 2026 (Purchase). Among the most active insiders: 오지수. Every trade is openly available.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
4 of 4 declarations
Meta Biomed是一家在XKRX市场上市的公司，专注于医疗保健和制药领域。该公司致力于开发和商业化医疗领域的创新解决方案。